Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous β1, 4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II

Authors

  • Claudia Ferrara,

    1. GLYCART biotechnology AG, Wagistrasse 18, CH-8952 Schlieren, Switzerland; telephone: +41 044 755 61 61; fax: +41 044 755 61 60
    2. Institute of Biotechnology, ETH Zürich, Zürich, Switzerland
    Search for more papers by this author
  • Peter Brünker,

    1. GLYCART biotechnology AG, Wagistrasse 18, CH-8952 Schlieren, Switzerland; telephone: +41 044 755 61 61; fax: +41 044 755 61 60
    Search for more papers by this author
  • Tobias Suter,

    1. GLYCART biotechnology AG, Wagistrasse 18, CH-8952 Schlieren, Switzerland; telephone: +41 044 755 61 61; fax: +41 044 755 61 60
    Current affiliation:
    1. Section of Clinical Immunology, University Hospital, CH-8044 Zürich, Switzerland.
    Search for more papers by this author
  • Samuel Moser,

    1. GLYCART biotechnology AG, Wagistrasse 18, CH-8952 Schlieren, Switzerland; telephone: +41 044 755 61 61; fax: +41 044 755 61 60
    Search for more papers by this author
  • Ursula Püntener,

    1. GLYCART biotechnology AG, Wagistrasse 18, CH-8952 Schlieren, Switzerland; telephone: +41 044 755 61 61; fax: +41 044 755 61 60
    Search for more papers by this author
  • Pablo Umaña

    Corresponding author
    1. GLYCART biotechnology AG, Wagistrasse 18, CH-8952 Schlieren, Switzerland; telephone: +41 044 755 61 61; fax: +41 044 755 61 60
    • GLYCART biotechnology AG, Wagistrasse 18, CH-8952 Schlieren, Switzerland; telephone: +41 044 755 61 61; fax: +41 044 755 61 60
    Search for more papers by this author

Abstract

The effector functions elicited by IgG antibodies strongly depend on the carbohydrate moiety linked to the Fc region of the protein. Therefore several approaches have been developed to rationally manipulate these glycans and improve the biological functions of the antibody. Overexpression of recombinant β1,4-N-acetylglucosaminyltransferase III (GnT-III) in production cell lines leads to antibodies enriched in bisected oligosaccharides. Moreover, GnT-III overexpression leads to increases in non-fucosylated and hybrid oligosaccharides. Such antibody glycovariants have increased antibody-dependent cellular cytotoxicity (ADCC). To explore a further variable besides overexpression of GnT-III, we exchanged the localization domain of GnT-III with that of other Golgi-resident enzymes. Our results indicate that chimeric GnT-III can compete even more efficiently against the endogenous core α1,6-fucosyltransferase (α1,6-FucT) and Golgi α-mannosidase II (ManII) leading to higher proportions of bisected non-fucosylated hybrid glycans (“Glyco-1” antibody). The co-expression of GnT-III and ManII led to a similar degree of non-fucosylation as that obtained for Glyco-1, but the majority of the oligosaccharides linked to this antibody (“Glyco-2”) are of the complex type. These glycovariants feature strongly increased ADCC activity compared to the unmodified antibody, while Glyco-1 (hybrid-rich) features reduced complement-dependent cytotoxicity (CDC) compared to Glyco-2 or unmodified antibody. We show that apart from GnT-III overexpression, engineering of GnT-III localization is a versatile tool to modulate the biological activities of antibodies relevant for their therapeutic application. © 2006 Wiley Periodicals, Inc.

Ancillary